Skip to search formSkip to main contentSkip to account menu

Metastatic Pancreatic Adenocarcinoma

An adenocarcinoma that arises from the exocrine pancreatic tissue and has metastasized to other anatomic sites.
National Institutes of Health

Related topics

Related topics

14 relations
Abdominal PainDiabetes MellitusEpithelial CellsEpithelium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Current management and future directions in metastatic pancreatic adenocarcinoma
Of the anticipated 50,000 individuals expected to be diagnosed with pancreatic cancer in 2016, the majority will have metastatic… 
Highly Cited
2010
Highly Cited
2010
Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma…
4010 Background: In a randomized phase II trial of F vs G in 88 MPA patients (pts), we reported that F induces a response rate… 
2009
2009
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens
Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the United States. Current 5-year survival is less than… 
2008
2008
Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study
Background: No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line… 
Highly Cited
2005
Highly Cited
2005
Immunohistochemistry Can Help Distinguish Metastatic Pancreatic Adenocarcinomas From Bile Duct Adenomas and Hamartomas of the Liver
Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well… 
Highly Cited
2004
Highly Cited
2004
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity… 
2004
2004
Salvage Chemotherapy with Mitomycin, Docetaxel, and Irinotecan (MDI Regimen) in Metastatic Pancreatic Adenocarcinoma: A Phase I and II Trial
Background: This study evaluates the maximum tolerated dose (MTD) and activity of mitomycin, docetaxel, and irinotecan (MDI… 
2001
2001
Adenocarcinoma arising in a transplanted pancreas.
Tumor transmission or de novo tumor development in the transplanted organ is a rare event. Appreciation of the organ-specific… 
Highly Cited
2000
Highly Cited
2000
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma
Although the novel cytidine analog gemcitabine has shown superior antitumor activity compared with weekly bolus 5‐fluorouracil in… 
1998
1998
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)